Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Daiichi Sankyo to Revise Its Midterm Business Plan Due to Transfer of Ranbaxy
May 20, 2014
- Sales of 25 Major Japan Drug Makers Up 10% as Top 4 Pharmas’ Offshore Revenues Flourish
May 19, 2014
- Blopress Generic to Go on Sale after June Listing, Japan’s 1st AG to Hit Shelves Before Rivals
May 19, 2014
- RaQualia, Kyoto University, iPS Academia Japan Announce Joint Research Agreement
May 19, 2014
- Jury Finds in Favor of Takeda in Actos Lawsuit, Turning Down Plaintiff’s Claim
May 19, 2014
- Olmesartan Sales Exceed 300 Billion Yen in FY2013: Daiichi Sankyo
May 16, 2014
- Generic Makers See Softer Sales Growth in FY2013
May 16, 2014
- Merck Deal Marks a Stride towards Top 3 in Global Ophthalmic Space: Santen Veep
May 16, 2014
- Daiichi Sankyo Chair Shoda to Bow Out, Become Adviser
May 16, 2014
- Nichi-Iko to Assign over 70 Sales Reps Specializing in DPC Hospitals within 2014
May 16, 2014
- Otsuka Holdings’ Pharmaceutical Sales Top 1 Trillion Yen for First Time
May 15, 2014
- Hisamitsu Takes Aim at 190 Billion Yen Sales in FY2018
May 15, 2014
- Ono to Introduce Sales Reps Specializing in Oncology for Entry to Oncology Market in Japan
May 15, 2014
- Zeria Appoints New President for First Time in 32 Years
May 14, 2014
- Meiji Seika Pharma Pres. Matsuo to Helm Holding Firm
May 14, 2014
- Eisai Sales Up 4.7% Thanks to Humira, Halaven Growth
May 14, 2014
- Santen Acquires Merck’s Eye Drugs in Japan, Key Markets
May 14, 2014
- 4 Major Wholesalers’ Average Operating Margin Tops 1% Mark, Signaling Biz Recovery
May 13, 2014
- Astellas FY2013 Sales Up 16% on Rosy Revenues from Xtandi, Betanis
May 13, 2014
- March Ethical Drug Sales Zoom 13.8% on Pre-Tax Hike Demand: Crecon Report
May 13, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…